Chris Hoggett
Senior Associate

Chris’ practice is in the pharmaceutical area of life sciences. He handles a broad range of subject-matter for innovator clients such as Gilead and Novartis, including NCE, formulation and medical use cases directed to commercially important products. Chris particularly enjoys working with clients in EPO opposition and appeal proceedings, and he has experience in defending patents covering blockbuster products against multiple opponents. He also advises on complementary aspects of pharmaceutical IP, including SPCs and regulatory law.

Prior to joining Carpmaels & Ransford, Chris graduated with a first-class MChem degree from the University of Durham. He was awarded the BP prize for his Master’s work on trimeric cyclic assemblies of calix[4]arene-tethered bismerocyanine dyes. As part of his degree, Chris spent a year on an Erasmus exchange in Prof. Dr. Frank Würthner’s laboratory at the University of Würzburg, Germany.

  • MChem (Hons) (University of Durham)
  • Chartered Patent Attorney
  • European Patent Attorney
Key Cases
  • Truvada® – Gilead v Teva & Generics (Formulations)
  • Biktarvy® (and other tenofovir alafenamide-containing products) – Gilead v four opponents (New chemical entities)
  • Genvoya® (and other cobicistat-containing products) – Gilead v multiple opponents (New chemical entities & combinations)
  • Tasigna® – Novartis v multiple opponents (Formulations & Polymorphs, enantiomers and salt forms)
  • Aclasta® – Novartis v multiple opponents (Dosage regimens)